相似文献
1
A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Pharm Stat. 2017 Jan;16(1):87-94. doi: 10.1002/pst.1790. Epub 2016 Nov 8.
2
Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Pharm Stat. 2018 Sep;17(5):541-554. doi: 10.1002/pst.1878. Epub 2018 Jul 29.
3
Sample size calculation for testing differences between cure rates with the optimal log-rank test.
J Biopharm Stat. 2017;27(1):124-134. doi: 10.1080/10543406.2016.1148711. Epub 2016 Feb 16.
4
Sample size calculation for the proportional hazards cure model.
Stat Med. 2012 Dec 20;31(29):3959-71. doi: 10.1002/sim.5465. Epub 2012 Jul 11.
5
A sample size formula for the supremum log-rank statistic.
Biometrics. 2005 Mar;61(1):86-91. doi: 10.1111/j.0006-341X.2005.031206.x.
6
Cancer immunotherapy trial design with cure rate and delayed treatment effect.
Stat Med. 2020 Mar 15;39(6):698-708. doi: 10.1002/sim.8440. Epub 2019 Nov 26.
7
Cancer immunotherapy trial design with long-term survivors.
Pharm Stat. 2021 Jan;20(1):117-128. doi: 10.1002/pst.2060. Epub 2020 Sep 1.
8
A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Stat Methods Med Res. 2021 May;30(5):1211-1234. doi: 10.1177/0962280220988570. Epub 2021 Apr 5.
9
Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Pharm Stat. 2020 Jul;19(4):358-369. doi: 10.1002/pst.1976. Epub 2020 Jan 12.
10
Sample size calculation for mixture cure model with restricted mean survival time as a primary endpoint.
Stat Methods Med Res. 2024 Sep;33(9):1546-1558. doi: 10.1177/09622802241265501. Epub 2024 Aug 6.
引用本文的文献
1
Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
Biom J. 2021 Oct;63(7):1406-1433. doi: 10.1002/bimj.202000043. Epub 2021 Jul 17.
2
Cancer immunotherapy trial design with cure rate and delayed treatment effect.
Stat Med. 2020 Mar 15;39(6):698-708. doi: 10.1002/sim.8440. Epub 2019 Nov 26.
3
A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
Stat Med. 2017 Nov 20;36(26):4121-4140. doi: 10.1002/sim.7421. Epub 2017 Aug 16.
本文引用的文献
1
Sample size calculation for testing differences between cure rates with the optimal log-rank test.
J Biopharm Stat. 2017;27(1):124-134. doi: 10.1080/10543406.2016.1148711. Epub 2016 Feb 16.
2
Sample size calculation for the proportional hazards cure model.
Stat Med. 2012 Dec 20;31(29):3959-71. doi: 10.1002/sim.5465. Epub 2012 Jul 11.
3
A SAS macro for parametric and semiparametric mixture cure models.
Comput Methods Programs Biomed. 2007 Feb;85(2):173-80. doi: 10.1016/j.cmpb.2006.10.008. Epub 2006 Dec 8.
4
A nonparametric mixture model for cure rate estimation.
Biometrics. 2000 Mar;56(1):237-43. doi: 10.1111/j.0006-341x.2000.00237.x.
5
Estimation in a Cox proportional hazards cure model.
Biometrics. 2000 Mar;56(1):227-36. doi: 10.1111/j.0006-341x.2000.00227.x.
6
A generalized F mixture model for cure rate estimation.
Stat Med. 1998 Apr 30;17(8):813-30. doi: 10.1002/(sici)1097-0258(19980430)17:8<813::aid-sim775>3.0.co;2-#.
7
The large sample distribution of the weighted log rank statistic under general local alternatives.
Lifetime Data Anal. 1997;3(1):5-12. doi: 10.1023/a:1009690200504.
8
The use of mixture models for the analysis of survival data with long-term survivors.
Biometrics. 1982 Dec;38(4):1041-6.
9
Designing clinical trials with arbitrary specification of survival functions and for the log rank or generalized Wilcoxon test.
Control Clin Trials. 1987 Sep;8(3):177-89. doi: 10.1016/0197-2456(87)90043-2.
10
A linear rank test for use when the main interest is in differences in cure rates.
Biometrics. 1989 Sep;45(3):899-904.
Zotero 插件